Analysts covering TNXP stock price forecast emphasize monitoring cash burn rate metrics in upcoming earnings to assess sustainability of R&D initiatives. See our latest analysis for Tonix Pharmaceuticals Holding Analysts peg shares as a moderate buy with a $4.50 price target. That implies 1,206% upside potential.